Clinical Study to Analyze the Safety and Efficacy of Molixan® as Part of Standard Therapy in the Treatment of Patients With the Severe Course of New Coronavirus Infection (COVID-19)
Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase III study.
The study is designed for 2 treatment groups:
Group 1 of the investigational drug - Patients receive standard therapy and the investigational drug.
Group 2 of comparison - Patients receive standard therapy and placebo.
100 项与 Pharma VAM 相关的临床结果
0 项与 Pharma VAM 相关的专利（医药）
100 项与 Pharma VAM 相关的药物交易
100 项与 Pharma VAM 相关的转化医学
